tbuckley/cabot-search huggingface dataset:
Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors
Authors: Mohammadali Hamiditabar, Muzammil Ali, Luke Bolek, Gelareh Vahdati, Izabela Tworowska, Ebrahim S. Delpassand
Journal: Clinical Nuclear Medicine (2017)

Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE is shown to be an effective therapeutic option for somatostatin-expressing neuroendocrine neoplasms. Some concerns are raised over safety of this modality in patients with a history of regional chemoembolization and radionuclide hepatic embolization (CRHE) and is cause of reluctance among some physicians for suggesting Lu-DOTATATE in this patient population.We retrospectively reviewed 143 patients with somatostatin-expressing neuroendocrine tumors who underwent Lu-DOTATATE PRRT. Statistical analysis was performed on effect of Lu-DOTATATE in patients with and without prior CRHE using resampling procedures and correlation coefficient (r).Proportion of toxicity in patients with and without CRHE was comparable (P = 0.246). No statistically significant correlation (r) found between any toxicity and prior CRHE (r = -0.3 to -0.03) or time elapsed between embolization and the first cycle of PRRT (r = -0.59 to 0.17). Following PRRT, 76.5% of patients with CRHE experienced benefit (partial response + stable disease), whereas 23.4% experienced progressive disease. Patients with CRHE showed more stable disease (P = 0.048) and less progressive disease (P = 0.046) following PRRT compared with no CRHE. The CRHE and no-CRHE status shared same probability for developing partial response/complete response following PRRT (P = 0.50).Treatment with Lu-DOTATATE did not show clinically or statistically significant toxicity in CRHE patients regardless of frequency of embolization or time interval between embolization and first PRRT. Results suggested a statistically significant higher response rate in patients with a history of CRHE. A prior history of CRHE is not a contraindication to subsequent PRRT.
Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial
Authors: Massimiliano Spaliviero, Nicholas E. Power, Katie S. Murray, Daniel D. Sjoberg, Nicole E. Benfante, Melanie L. Bernstein, James Wren, Paul Russo, Jonathan A. Coleman
Journal: European Urology (2017)
Abstract #5441: Identification of biomarkers of vascular disrupting agent activity during AVE8062 phase I trials in solid tumors
Authors: Françoise Farace, Christophe Massard, Ratislav Bahleda, Melissa Taylor, Patrick Cohen, Thomas Tursz, Jean Charles Soria
Journal: Cancer Research (2009)

Vascular disrupting agents (VDA) are a new class of anti-cancer agents that show specificity in disrupting established tumor vessels. Current challenges for VDA development are identifying surrogate pharmodynamic biomarkers to monitor drug bioactivity and dosing and to predict treatment efficacy. Circulating Endothelial cells (CEC), Circulating Endothelial Progenitor cells (CEP) and plasmatic proteins were monitored in a total of 27 patients recruited in two phase I studies with AVE8062 alone or combined with cisplatin.  Methods : CEC were measured in all pts at baseline, 24 hrs and day 7 of treatment with AVE8062. Additional time points were assessed at 6 hrs and 10 hrs in 10 pts. CECs were measured in one ml erythocyte lysed whole blood by four-color flow cytometry (FCM) and identified by a CD45 - CD31 + CD146 +  7-amino-actinomycin (7AAD) -  phenotype according to a method we established previously (1). CEPs were measured at baseline, day 2 or 3 and day 7 in progenitor-enriched fractions and identified by FCM as extremely rare events with a CD45 dim CD34  +  VEGFR2 + 7AAD -  phenotype. P-selectin, E-selectin, VCAM-1, MMP2, VEGF, sVEGFR2, MMP9 and SDF1 were measured at baseline, 24 hrs and day 7.  Results : Fifteen pts out of 27 presented a significant increase in CECs in the 24hrs samples compared to baseline. When the kinetics of CEC were monitored in 8 pts, 3 pts presented sustained peaks of CECs at 10hrs while 3 others had peaks at 24 hrs. With regard to the dose of AVE8062, the number of patients presenting a peak in CEC counts was greater with higher AVE8062 doses suggesting that CEC levels might depend on AVE8062 dose. Peaks of CEPs were detected in 15 pts either at day 3 or day 7 of AVE8062 infusion. No change was observed in plasmatic levels of P-selectin, E-selectin, VCAM-1, MMP2, VEGF, sVEGFR2. MMP9 levels were significantly increased at 24hrs (p Conclusion:  These results strongly suggest that CEC counts could be a useful pharmacodynamic marker of AVE8062 activity allowing to monitor the importance of vascular damage and assist in effective dose identification. MMP9, probably released as a consequence of tumor lesion, might have a major role in the mobilization of CEPs recruited for tumor vascular repair. CECs, CEPs, MMP9 and SDF1 levels are interesting potential biomarkers of VDA activity and may help elucidate the mechanism of action of these novel agents. (1) Jacques N, Vimond N, Conforti R, Griscelli F, Lecluse Y, Laplanche A, Malka D, Vielh P, Farace F. Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J.Immunol.Methods 2008;337:132-43   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5441.
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Marianne E Pavel, Simron Singh, Jonathan R Strosberg, Lida Bubuteishvili-Pacaud, Evgeny Degtyarev, Maureen P Neary, Carlo Carnaghi, Jiri Tomasek, Edward Wolin, Markus Raderer, Harald Lahner, Juan W Valle, Rodney Pommier, Eric Van Cutsem, Margot E T Tesselaar, Gianfranco Delle Fave, Roberto Buzzoni, Matthias Hunger, Jennifer Eriksson, David Cella, Jean-François Ricci, Nicola Fazio, Matthew H Kulke, James C Yao
Journal: The Lancet Oncology (2017)
Outcomes in Guideline-Based Versus Off-Guideline Primary Prevention Implantable Cardioverter-Defibrillator Recipients
Authors: William Escande, Serge Boveda, Pascal Defaye, Christophe Leclercq, Nicolas Sadoul, Marie-Cecile Perier, Jean-Claude Deharo, Laurent Fauchier, Eloi Marijon, Olivier Piot
Journal: Journal of the American College of Cardiology (2017)
Epidemiology of Sepsis Among Adolescents at Community Hospital Emergency Departments
Authors: Idris V. R. Evans, R. Scott Watson, Joseph Carcillo, Derek C. Angus, Christopher W. Seymour
Journal: JAMA Pediatrics (2017)

In 2012, Rory Staunton, a healthy 12-year-old boy, presented to the emergency department (ED) of a community hospital in New York with symptoms that, in retrospect, were determined to be caused by sepsis. He was seen, discharged, and subsequently died of septic shock. Consequently, the governor introduced Rory’s Regulations, which mandated that hospitals in New York implement protocols to recognize and treat sepsis according to evidence-based guidelines. These efforts may result in large public health benefits for patients. However, crucial to Rory’s case was that his diagnosis was missed. Efforts to avoid missed or delayed diagnosis are greatly enhanced by knowledge of the frequency and course of similar cases, yet such data are unknown. We therefore examined the electronic health records of healthy adolescents who presented to 12 community hospital EDs in southwestern Pennsylvania during the same period (January 1, 2010, through December 31, 2012) with signs and symptoms similar to those of Rory Staunton.
Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol 2016;70:588–96
Authors: Nicola Fossati, Giorgio Gandaglia, Alberto Bossi, Francesco Montorsi, Alberto Briganti
Journal: European Urology (2016)
TGF‐βスーパー遺伝子ファミリーの骨形成蛋白質による骨形成の相乗的誘導【Powered by NICT】
Authors: Ripamonti Ugo, Parak Ruqayya, M Klar Roland, Dickens Caroline, Dix-Peek Therese, Duarte Raquel
Journal: Biomaterials (2016)
骨再生の増強のための絹フィブロインナノヒドロキシアパタイト足場からのSDF‐1とBMP‐2の逐次および徐放性【Powered by NICT】
Authors: Shen Xiaofeng, Zhang Yanxia, Gu Yong, Xu Yun, Liu Yong, Li Bin, Chen Liang
Journal: Biomaterials (2016)
From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation
Authors: C Jiménez, S Alonso-Álvarez, M Alcoceba, G R Ordóñez, M García-Álvarez, M I Prieto-Conde, M C Chillón, A Balanzategui, R Corral, L A Marín, N C Gutiérrez, N Puig, M E Sarasquete, M González, R García-Sanz
Journal: Blood Cancer Journal (2017)

Abstract Transformation of Waldenström’s macroglobulinemia (WM) to diffuse large B-cell lymphoma (DLBCL) occurs in up to 10% of patients and is associated with an adverse outcome. Here we performed the first whole-exome sequencing study of WM patients who evolved to DLBCL and report the genetic alterations that may drive this process. Our results demonstrate that transformation depends on the frequency and specificity of acquired variants, rather than on the duration of its evolution. We did not find a common pattern of mutations at diagnosis or transformation; however, there were certain abnormalities that were present in a high proportion of clonal tumor cells and conserved during this transition, suggesting that they have a key role as early drivers. In addition, recurrent mutations gained in some genes at transformation (for example, PIM1 , FRYL and HNF1B ) represent cooperating events in the selection of the clones responsible for disease progression. Detailed comparison reveals the gene abnormalities at diagnosis and transformation to be consistent with a branching model of evolution. Finally, the frequent mutation observed in the CD79B gene in this specific subset of patients implies that it is a potential biomarker predicting transformation in WM.
健忘性軽度認知障害における異常な自発的低周波数脳活動:安静時f MRI研究のメタ分析【Powered by NICT】
Authors: Pan PingLei, Zhu Lin, Yu TingTing, Shi HaiCun, Zhang Bing, Qin Ruomeng, Zhu Xiaolei, Qian Lai, Zhao Hui, Zhou Hong, Xu Yun
Journal: Ageing Research Reviews (2017)
癌ワクチンの効力を改善するためのリンパ節ターゲッティング能力を有する高分子ハイブリッドミセルの調整【Powered by NICT】
Authors: Zeng Qin, Li Hanmei, Jiang Hao, Yu Jiao, Wang Ying, Ke Huan, Gong Tao, Zhang Zhirong, Sun Xun
Journal: Biomaterials (2017)
6.5‐Frシースレスガイドカテーテルと6‐Frグライドシースを用いた経橈骨動脈冠動脈インターベンションのランダム化比較
Authors: Saigan Makoto, Horie Kazunori, Miyasaka Masaki, Osai Norichika, Isawa Tsuyoshi, Matsumoto Takashi, Sakurai Mie, Tada Norio, Takizawa Kaname, Inoue Naoto, Meguro Taiichiro
Journal: Circulation (2016)
ナノ構造組換えサイトカイン:短寿命予防への高度に安定な代替【Powered by NICT】
Authors: Torrealba Debora, Parra David, Seras-Franzoso Joaquin, Vallejos-Vidal Eva, Yero Daniel, Gibert Isidre, Villaverde Antonio, Garcia-Fruitos Elena, Roher Nerea
Journal: Biomaterials (2016)
Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis
Authors: Claudia C. Dobler, Kelvin Cheung, John Nguyen, Andrew Martin
Journal: European Respiratory Journal (2017)

There is uncertainty regarding whether patients with cancer should be screened for latent tuberculosis infection (LTBI). We performed a systematic review and meta-analysis to estimate the relative incidence of tuberculosis (TB) in cancer. We searched MEDLINE and Embase for studies published before December 21, 2016. We included studies that evaluated the incidence of TB in patients with solid cancers and haematological malignancies relative to a reference group (study control or general population). A pooled estimate of the incidence rate ratio (IRR) was obtained using standard meta-analysis methods. The search strategy identified 13 unique studies including 921 464 patients with cancer. The IRR of TB for adult patients with cancer was 2.61 (95% CI 2.12–3.22; I 2 =91%). In haematological cancers, the IRR was 3.53 (95% CI 1.63–7.64; I 2 =96%); and in solid cancers in adults, it was 2.25 (95% CI 1.96–2.58; I 2 =91%). The highest IRR was found in children with haematological malignancies or solid cancers (IRR 16.82, 95% CI 8.81–32.12; I 2 =79%). Considering the limited duration of maximum immunosuppression in cancer and reduced cumulative lifetime risk of TB because of reduced life expectancy, children, but not adults, appear to be at a sufficient level of risk to warrant systematic screening for LTBI.
Severe disruption and disorganization of dermal collagen fibrils in early striae gravidarum
Authors: F. Wang, K. Calderone, T.T. Do, N.R. Smith, Y.R. Helfrich, T.R.B. Johnson, S. Kang, J.J. Voorhees, G.J. Fisher
Journal: British Journal of Dermatology (2017)

Striae gravidarum (SG), or stretch marks of pregnancy, begin as erythematous streaks and mature into hypopigmented atrophic bands. In order to investigate molecular alterations that may promote atrophy of SG, we investigated dermal type I collagen fibrils, which provide human skin with support. We obtained skin samples of recently developed, erythematous abdominal SG from pregnant women. To examine the organization of collagen fibrils, second‐harmonic generation imaging was performed using multiphoton microscopy. Immunostaining was used to determine protein expression and localization of type I procollagen, the precursor of type I collagen fibrils. Real‐time polymerase chain reaction was used to determine gene expression levels. In control (hip) and stretched normal‐appearing perilesional abdominal skin, dermal collagen fibrils were organized as tightly packed, interwoven bundles. In SG, collagen bundles appeared markedly separated, especially in the mid‐to‐deep dermis. In the spaces separating these bundles, loosely packed wavy collagen fibrils lacking organization as bundles were present. These disorganized fibrils persisted into the postpartum period and failed to form densely packed bundles. Numerous large fibroblasts displaying type I procollagen expression were in close proximity to the disorganized fibrils, suggesting that the fibrils are newly synthesized. Supporting this possibility, immunostaining and gene expression of type I procollagen were increased throughout the dermis of SG. Early SG display marked separation of collagen bundles and emergence of disorganized collagen fibrils that fail to form bundles. These alterations may reflect ineffective repair of collagen bundles disrupted by intense skin stretching. Persistent disruption of the collagenous extracellular matrix likely promotes formation and atrophy of SG.
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Authors: Sandro Pignata, Giovanni Scambia, Alessandra Bologna, Simona Signoriello, Ignace B. Vergote, Uwe Wagner, Domenica Lorusso, Viviana Murgia, Roberto Sorio, Gabriella Ferrandina, Cosimo Sacco, Gennaro Cormio, Enrico Breda, Saverio Cinieri, Donato Natale, Giorgia Mangili, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Vanda Salutari, Francesco Raspagliesi, Laura Arenare, Alice Bergamini, Jane Bryce, Gennaro Daniele, Maria Carmela Piccirillo, Ciro Gallo, Francesco Perrone
Journal: Journal of Clinical Oncology (2017)

Purpose Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective with a longer time interval from previous platinum treatment (platinum-free interval [PFI]). In 1999, it was hypothesized that prolonging PFI with single-agent non-PBC (NPBC) may offer a strategy to improve overall outcome. MITO-8 aimed to verify this hypothesis commonly used in clinical practice although it has not been prospectively tested. Methods MITO-8 is an open-label, prospective, randomized, superiority trial. Patients with OC who experienced disease progression 6 to 12 months after their last platinum treatment were randomly assigned 1:1 to the experimental sequence of NPBC followed by PBC at subsequent relapse or the standard reverse treatment sequence. Overall survival (OS) was the primary end point. Results Two hundred fifteen patients were enrolled (standard arm [n = 108]; experimental arm [n = 107]). The trial ended before planned because of slow enrollment. PFI was prolonged in the experimental arm (median, 7.8 v 0.01 months). There was no OS benefit in the experimental arm (median, 21.8 v 24.5 months; hazard ratio, 1.38; 95% CI, 0.99 to 1.94; P = .06). Progression-free survival after the sequence was significantly shorter in the experimental arm (median, 12.8 v 16.4 months; hazard ratio, 1.41; 95% CI, 1.04 to 1.92; P = .025). Global quality-of-life change after three cycles was worse in the experimental arm. Slight differences were observed in the incidence of adverse effects. Conclusion MITO-8 supports the recommendation that PBC not be delayed in favor of an NPBC in patients with partially platinum-sensitive OC. PBC should be used as a control arm in future trials of new drugs in this setting.
AB0932 Prevalence of type d personality in turkish patients with fibromyalgia syndrome
Authors: Y Garip, T Guler, OB Tuncer, S Onen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Type D personality is a distressed personality type involving two personality traits, namely negative affectivity and social inhibition, which are described as tendency to experience negative emotions and to inhibit self-expression in social relationships, respectively (1). <h3>Objectives</h3> The present study investigated the prevalence of type D personality in Turkish patients with fibromyalgia (FM) and evaluated the association between type D personality and clinical parameters of FM. Although there is adequate number of studies focusing on the relation between FM and psychological conditions such as depression and anxiety; this topic has been rarely addressed in the literature. <h3>Methods</h3> A total of 100 patients with FM fulfilling 1990 American College of Rheumatology (ACR) diagnostic criteria and 50 healthy controls were included. Type D personality was assessed by Type D Scale-14 (DS-14). FM disease severity was determined by Fibromyalgia Impact Questionnaire (FIQ), functional status by Stanford Health Assessment Questionnaire (HAQ), and health-related quality of life (HRQoL) by Nottingham Health Profile (NHP). Severity of pain and fatigue were measured by Visual Analog Scale (VAS). <h3>Results</h3> Prevalence of type D personality was 33% in FM patients, and 12% in controls. It was higher in the patients with FM (Odds ratio (OR) =3.612 confidence interval (CI) 95% (1.398–9.333)) (p&lt;0.01) compared with controls. Type D FM patients scored higher in tender point count (TPC), FIQ, HAQ, VAS-pain and all NHP subgroups except energy (p&lt;0.01) (Table 1). Type D personality was found as correlated with FIQ, TPC, HAQ, VAS-pain and NHP subgroups except energy (p&lt;0.01). <h3>Conclusions</h3> Type D personality is prevalent among Turkish patients with FM, with a rate of 33%. It is associated with poor HRQoL regarding pain, physical mobility, sleep, and social and emotional functions. Based on our findings, assessment of personality characteristics of the patients with FM may hold the key for the treatment of the disease. Presence of type D personality should be taken into account in FM in order to develop new treatment strategies for the patients who have inadequate response to conventional therapies. <h3>References</h3> Denollet J. Type D personality: a potential risk factor refined. J Psychosom Res 2000;49:255–66. <h3>Disclosure of Interest</h3> None declared
全身性遺伝子デリバリー担体としてのポリ(エチレングリコール)‐ポリ(L‐リジン)ブロック共重合体からのポリプレックスミセルの構造と機能に及ぼすせん断応力の影響【Powered by NICT】
Authors: M Takeda Kaori, Yamasaki Yuichi, Dirisala Anjaneyulu, Ikeda Sorato, A Tockary Theofilus, Toh Kazuko, Osada Kensuke, Kataoka Kazunori
Journal: Biomaterials (2017)
Early comprehensive physiotherapy after lumbar spine surgery (PEDro synthesis)
Authors: Gustavo C Machado, Marina B Pinheiro
Journal: British Journal of Sports Medicine (2017)

Snowdon M, Peiris CL. Physiotherapy commenced within the first four weeks post-spinal surgery is safe and effective: a systematic review and meta-analysis. Arch Phys Med Rehabil 2016;97:292–301.

A small subgroup of patients with low back pain have significant neurological deficit or radicular syndrome secondary to lumbar disc herniation.1 Some patients opt for surgery without considering any conservative care, and for those whom conservative care does not bring relief, referral to surgery (such as discectomy) is common.2 However, many patients have persistent postoperative symptoms, including pain and reduced functional capacity.3 Early referral to physiotherapy is not routine practice, since surgeons typically place mobility restrictions for the first 6 weeks after surgery. However, there is evidence questioning this precautionary approach to postoperative care.4 Physiotherapy interventions could potentially improve outcomes soon after surgery,5 although it is still largely unknown whether early commencement of physiotherapy is safe and beneficial to patients after lumbar disc surgery.

The aim of the systematic review was to determine whether early comprehensive physiotherapy rehabilitation commenced within 4 weeks post lumbar disc surgery is safe and effective compared with a control group.

Electronic searches were conducted on Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medline, Allied and Complementary Medicine Database (AMED), PubMed, …
Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia
Authors: Stefan P. Tarnawsky, Rebecca J. Chan, Mervin C. Yoder
Journal: Journal of Clinical Investigation (2017)

Juvenile myelomonocytic leukemia (JMML) is a pediatric myeloproliferative neoplasm that bears distinct characteristics associated with abnormal fetal development. JMML has been extensively modeled in mice expressing the oncogenic KrasG12D mutation. However, these models have struggled to recapitulate the defining features of JMML due to in utero lethality, nonhematopoietic expression, and the pervasive emergence of T cell acute lymphoblastic leukemia. Here, we have developed a model of JMML using mice that express KrasG12D in multipotent progenitor cells (Flt3Cre+ KrasG12D mice). These mice express KrasG12D in utero, are born at normal Mendelian ratios, develop hepatosplenomegaly, anemia, and thrombocytopenia, and succumb to a rapidly progressing and fully penetrant neonatal myeloid disease. Mutant mice have altered hematopoietic stem and progenitor cell populations in the BM and spleen that are hypersensitive to granulocyte macrophage-CSF due to hyperactive RAS/ERK signaling. Biased differentiation in these progenitors results in an expansion of neutrophils and DCs and a concomitant decrease in T lymphocytes. Flt3Cre+ KrasG12D fetal liver hematopoietic progenitors give rise to a myeloid disease upon transplantation. In summary, we describe a KrasG12D mouse model that reproducibly develops JMML-like disease. This model will prove useful for preclinical drug studies and for elucidating the developmental origins of pediatric neoplasms.
TET1 Regulates DNA Replication through Targeting of Minichromosome Maintenance Genes
Authors: Hengyou Weng, Huilin Huang, Xi Qin, He Huang, Okwang Kwon, Ping Chen, Xi Jiang, Chao Hu, Hao Huang, Yungui Wang, Stephen Arnovitz, Shenglai Li, Jennifer Strong, Kyle Ferchen, Rui Su, Lei Dong, Chenying Li, Mary Beth Neilly, Zejuan Li, Jason Stewart, Carolyn Price, Yingming Zhao, Jianjun Chen
Journal: Blood (2016)